Related Experiment Video

Updated: Jun 13, 2026

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Gefitinib for the treatment of non-small-cell lung cancer

Lynn Campbell1, Fiona Blackhall, Nicholas Thatcher

  • 1Christie Hospital NHS Foundation Trust, Medical Oncology, Wilmslow Road, Manchester, UK. lrcampbell@doctors.org.uk

Expert Opinion on Pharmacotherapy
|April 30, 2010
PubMed
Abstract

Insights

Gefitinib shows promise for non-small-cell lung cancer (NSCLC) treatment, especially in patients with EGFR mutations. This EGFR inhibitor offers improved outcomes and quality of life compared to chemotherapy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Clinical Trials

Background:

  • Epidermal growth factor receptor (EGFR) is a key target in non-small-cell lung cancer (NSCLC) therapy.
  • Gefitinib, an EGFR inhibitor, has demonstrated clinical utility in recent trials.
  • Identifying predictive biomarkers is crucial for optimizing gefitinib treatment efficacy.

Purpose of the Study:

  • To review the clinical evidence and impact of gefitinib in NSCLC treatment.
  • To summarize landmark clinical trials evaluating gefitinib.
  • To highlight the role of biomarkers in predicting gefitinib response.

Main Methods:

  • Systematic literature search of Medline, ASCO, and WCLC abstracts (2000-2010).
  • Analysis of Phase III INTEREST and IPASS studies comparing gefitinib with chemotherapy.
  • Review of subsequent studies (WJOG4305, NEJ002) focusing on EGFR mutation-positive patients.

Main Results:

  • Gefitinib demonstrated non-inferiority to docetaxel in pretreated patients (INTEREST study), with improved quality of life and toxicity.
  • Gefitinib showed improved progression-free survival versus chemotherapy in chemotherapy-naive patients with adenocarcinoma and specific smoking history (IPASS study).
  • Activating EGFR mutations were strongly associated with superior outcomes when treated with gefitinib.

Conclusions:

  • Gefitinib is a valuable treatment option for pretreated and selected chemotherapy-naive advanced NSCLC patients.
  • Activating EGFR mutations are predictive biomarkers for gefitinib efficacy.
  • Gefitinib is expected to significantly impact NSCLC management, particularly in biomarker-selected populations.

More Related Videos

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds13:34

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...